Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK2 | O96017 | 14/20 | 0.69 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | THRB | P10828 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.61 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.60 |
| ▸ | ACHE | P22303 | 2/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4188962 | 0.88 | MEN1 (0.76) | CHEK2MEN1KMT2ATHRBKDM4E | |
| SCHEMBL5636118 | 0.85 | CHEK2 (0.63) | CHEK2KDM4EALDH1A1TP53MAPT | |
| SCHEMBL8396715 | 0.82 | ALDH1A1 (0.81) | CHEK2MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL6641749 | 0.82 | CHEK2 (1.00) | CHEK2MEN1KMT2ATHRB | |
| SCHEMBL20445326 | 0.82 | SLC2A1 (0.68) | CHEK2MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL5635322 | 0.78 | CHEK2 (0.81) | CHEK2MEN1KMT2ATHRB | |
| SCHEMBL31612805 | 0.77 | HPSE (0.86) | CHEK2MEN1KMT2ATHRBKDM4E | |
| SCHEMBL28256337 | 0.77 | NPC1 (0.66) | CHEK2MEN1KMT2ATHRBKDM4E | |
| SCHEMBL6645851 | 0.77 | CHEK2 (1.00) | CHEK2MEN1KMT2ATHRB | |
| SCHEMBL3919848 | 0.77 | CHEK2 (1.00) | CHEK2MEN1KMT2ATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7504414-B2 | Substituted benzimidazoles and imidazo-[4,5]-pyridines | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-20080009493-A1 | Substituted Benzimidazoles and Imidazo-[4,5]-Pyridines | ARIENTI KRISTEN L | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009493-A1 | Substituted Benzimidazoles and Imidazo-[4,5]-Pyridines | CDKN1A, DDB1, TMBIM6 | CHEK2 14/4885MEN1 1940/4885KMT2A 4404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.